DAI Magister Appoints Steve Bachmann as Head of US and Co-Head of Europe - Featured Image | CEO Monthly

DAI Magister Appoints Steve Bachmann as Head of US and Co-Head of Europe

Splitting his time between the US and European markets, Bachmann is responsible for driving the company’s continued growth in both regions

DAI Magister, a boutique investment bank, has announced the appointment of Steve Bachmann as Head of US and Co-Head of Europe. Bachmann brings over 30 years of experience in software-driven M&A advisory services to the role, leading more than 100 M&A or investment transactions in the process.

Prior to joining DAI Magister, Bachmann was a Managing Director at Atlas Technology Group, where he worked for almost a decade, providing M&A and capital-raising services to software companies. 

Bachmann also launched and managed Broadview’s London office, which he grew to a third of the company’s total revenue. Subsequently, he returned to the US and founded Broadview Capital Partners, a $250m late-stage venture fund, where he was a General Partner. 

Bachmann said: “I’m thrilled to have joined a company that is intent on driving innovation across a range of pivotal sectors, from climate tech to deep tech to fintech. By enabling access to capital for start-ups and growth stage companies through both M&A and capital-raising advisory services, I hope to support DAI Magister’s mission to expand the reach and impact of organisations that are accelerating the speed of global technological growth.

“The US and Europe are mature markets, but there’s still significant volumes of untapped potential in each region. I’m confident that we can expand DAI Magister’s presence in both areas by building relationships between founders, investors and future strategic acquirors, ensuring that pioneering tech solutions receive the attention they deserve in the process.

“The knowledge I have accrued over three decades in the M&A advisory space will equip me with the skills needed to facilitate DAI Magister’s continued growth. With the volume of M&A deals rebounding in the first quarter of the year, this is the perfect time to begin this role and start exploring the possibility of strategic exits for new and existing clients.”

Victor Basta, CEO of DAI Magister, expressed his excitement about Steve joining the team, stating: “I know Steve well from our time working together at Broadview, and I’m delighted to be bringing on board a seasoned professional with a wealth of industry understanding. Steve will be a vital part of our efforts to grow our footprint in the US and Europe, while simultaneously supporting our clients’ efforts to navigate the financial elements of growth, expansion and strategic investments.”

Steve Bachmann
Want to Be Recognised? Enter Our Awards Today!

Learn how to get recognised for your achievements and become a nominee in our prestigious awards programmes. Discover the criteria and steps needed to showcase your leadership excellence.

Find Out More
Get recognised banner - woman holding device

You might also like

Explore insights and updates tailored for business leaders and innovators, curated to inspire success.

December 5, 2017 Uniquely and Exceptionally Experienced Real Estate Fund Manager in Asia

ARA Korea Limited (ARA Korea) is a full-service real estate fund management company based in Seoul, Korea. Anthony Kang, CEO of the Year 2017, provides us with a breakdown of the firm’s products and services, as well as outlining the company’s ove...

October 9, 2023 Pioneering Lifecycle Management for the Internet of Things

RIoT Secure AB is a Stockholm based tech firm who specialise in the secure lifecycle management of the Internet of Things (IoT). It covers all sizes of device, large or small, with an aim to make essential security more accessible to device manufa...

December 21, 2017 Accelerate Biotechnology

Batavia Biosciences focuses on accelerating the transition of biopharmaceutical product candidates from discovery to the clinic with improved success and lower cost. The firm is people’s flexible partner to rely on at all stages of biopharmaceutic...